|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07K 16/18 | (2006.01) |
| C12N 15/13 | (2006.01) | ||
| C12N 5/10 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 1481992 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04011466.2 |
| Date of filing the European patent application | 2001-02-26 | |
| (97) | Date of publication of the European application | 2004-12-01 |
| (45) | Date of publication and mention of the grant of the patent | 2016-11-02 |
| (46) | Date of publication of the claims translation | 2017-02-10 |
| (30) | Number | Date | Country code |
| 184601 P | 2000-02-24 | US | |
| 254465 P | 2000-12-08 | US | |
| 254498 P | 2000-12-08 | US |
| (72) |
Holtzman, David, M., US
Demattos, Ronald, US
Bales, Kelly, R., US
Paul, Steven, M., US
Tsurushita, Naoya, US
Vasquez, Maximiliano, US
|
| (73) |
Eli Lilly & Company,
Lilly Corporate Center, Indianapolis, IN 46285,
US
WASHINGTON UNIVERSITY ST. LOUIS, 1 Brookings Drive,, St. Louis Missouri 63110, US |
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Humanizuoti antikūnai, kurie sekvestruoja amiloidinį beta peptidą |
| Humanized antibodies that sequester amyloid beta peptide |
| Payment date | Validity (years) | Amount | |
| 2020-02-11 | 20 | 347.00 EUR |